Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics.
Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures.
In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organization responsible for the development of AbbVie's portfolio of early and late-stage clinical preregistration pipeline compounds as well as marketed compounds across a range of therapeutic areas. Dr Brun received his M.D. at The Johns Hopkins University School of Medicine.
Forte Biosciences, Inc. is a biopharmaceutical company and the lead product, FB-102, is a proprietary molecule with potentially broad autoimmune applications.
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP
RemeGen's Telitacicept receives US FDA Fast Track Designation
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis